Collegium and Grünenthal settle Nucynta patent litigation

Collegium Pharmaceutical reported in an 8-K that it and Grünenthal GmbH entered into a settlement agreement on October 15, 2026 to resolve all disputes and claims between the parties, including the Nucynta Litigation.¹ The filing itself was signed on October 19, 2026 by Colleen Tupper, Collegium's Executive Vice President and Chief Financial Officer.

The dispute traced back to February 2026, when Grünenthal filed a complaint in the United States District Court for the District of New Jersey, naming the Company as a defendant, for patent infringement related to the launch of the authorized generic for Nucynta ER.¹

Under the settlement, the parties mutually agreed to terminate the Grünenthal License in its entirety and the Consent Agreement solely with respect to the Territory, effective on October 15, 2026 following the Company's payment to Grünenthal of $17,000,000.¹ Collegium said all obligations of the Company with respect to royalties under the Grünenthal License have been fully and finally discharged and no further royalties will be due pursuant to the Grünenthal License.¹ Outside of the territory-specific termination, the Consent Agreement shall continue in full force and effect in accordance with its terms.¹

As part of the resolution, Grünenthal has also, among other things, assigned certain patents related to the Nucynta Products to the Company and filed a motion to dismiss the Nucynta Litigation.¹ The original license and consent agreement underlying the dispute dated to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal, which the Company assumed pursuant to a Consent Agreement, dated as of January 30, 2020, as part of the Company's 2020 acquisition of Nucynta ER and Nucynta IR.¹